Clozapine binds and has significant effects on multiple neurotransmitter receptors, notably 21 including some dopamine receptors. Downstream of these receptors, clozapine affects the 22 balance of Gi-and Gq-dependent second-messenger signaling. We used Caenorhabiditis elegans 23 as a genetic model to study further how clozapine affects both dopamine receptors and 24 downstream Gq mediated signaling. Four of six worm dopamine receptor orthologs, dop-1, dop-25 2, dop-4, and dop-5 produced resistance to clozapine induced developmental delay when 26 mutated, suggesting that both type I and type II dopamine receptors mediate the behavioral 27 effects of clozapine in C. elegans. Beyond these receptors, reduction of function of one of the G 28 proteins, egl-30 (Gαq), produced greatly increased susceptibility to clozapine. Gαq has multiple 29 known downstream effects. Among these is the control of acetylcholine release, which is in 30 balance with monoamines in the human brain and is another target of clozapine and other 31 antipsychotic drugs. We tested for downstream effects on acetylcholine at the neuromuscular 32 junction upon clozapine treatment but found no evidence for effects of clozapine. In contrast, 33 modulation of Gαq upstream leads to worms that are either more resistant or more susceptible to 34 clozapine, emphasizing the importance of Gαq proteins in mediating effects of clozapine. A 35 genetic screen for suppressors of egl-30 recovered eight mutants. By characterizing the 36 behavioral effects of these mutants, we found that clozapine exerts its function on development 37 by affecting Gαq signaling through control of the pharyngeal pumping rate. A whole-genome 38 sequencing technique was utilized and identified a list of candidate genes for these suppressor 39 mutations. Further characterization of these mutants promises the discovery of novel components 40 participating in Gαq signaling and a better understanding of the mechanisms of action of 41 clozapine. 42 43 Clozapine is an atypical antipsychotic drug (APD), mainly used for schizophrenia that does not 44 improve following the use of standard antipsychotic medications. The pharmacology of 45 clozapine shares some features with other APDs, but other features are unique, and its sites of 46 action are especially complex. 47 48 Standard antipsychotic drugs are thought to achieve some of their important effects (both 49 beneficial and unwanted) by acting as antagonists or partial agonists at D2 receptors (JONES AND 50 PILOWSKY 2002). In humans, there are five distinct G-protein coupled dopamine (DA) receptors, 51 and they are divided into two major subtypes: D1-like (D1 and D5) and D2-like (D2, D3 and D4) 52 (CUMMING 2011). These two classifications were originally assigned based on the receptor's 53 effect on cyclic AMP levels, but also reflect genetic homologies. Selective pharmacological 54 agents and receptor knockouts have been applied to demonstrate that signaling through D1-like 55 and D2-like receptors have opposite effects on many aspects of cell activation and some 56 behaviors (KELLY et al. 1998; GONG et al. 1999; MCNAMARA et al. 2003) . However, 57 simultaneous stimulation of both D1 and D2 type receptors shows that these receptors also have 58 synergistic effects on certain behaviors (PLAZNIK et al. 1989; GONG et al. 1999) . By comparison 59 to standard antipsychotic medications, clozapine binds weakly to D2, more strongly to D4, 60 among dopamine type II receptors, and most strongly to Type I dopamine receptors, including 61 the D1 receptor. It also binds with high affinity to histamine (H1), acetylcholine muscarinic 62 (M1), α-adrenergic (α1), and multiple serotonin (5-HT2A, 5-HT2C, 5-HT7) receptors (NAHEED 63 AND GREEN 2001).
Introduction
G protein mediated effects of clozapine have been studied in cultured cells and mammals. In it has been found that clozapine binds the mGluR2/2AR receptor heterocomplex, which also 116 alters the balance of Gi-and Gq-dependent signaling (FRIBOURG et al. 2011) . 117 118 In our laboratory, we have used the well-documented clozapine-induced developmental 119 delay/lethality phenotype in C. elegans to study the mechanisms of action of clozapine. We The developmental drug assay was performed as previously described in (HAO AND BUTTNER 143 2014). In brief, well-grown adult animals were treated in bleach solution (hypochlorite:1 N 144 NaOH:ddH2O(1:4:5)) to obtain synchronized eggs. 25 synchronized eggs were then placed onto 145 12-well NGM assay plates containing variable concentrations of drugs. The drugs were initially 146 dissolved in DMSO to obtain 80 mM stock solutions, which were diluted into 1.7 mM acetic 147 acid. Treated worms were transferred onto the NGM plates. Every 24 hours thereafter, the plates 148 were observed and the developmental status of the worms was recorded. For each worm strain, 149 the experiment was repeated at least three times. The concentration of clozapine was adjusted 150 according to the sensitivity of the tested worm strain. We present results from the third day of 151 observation, as results at this time optimally identify and represent the phenotype of strains with 152 different growth characteristics.
154
Worm Behavioral assays 155 The worms used for behavioral assays were staged young adult worms. Unless stated otherwise, 156 these were obtained by picking well-grown L4 worms onto NGM plates 24 h before the assay to 157 allow them grow to young adulthood. For the pharyngeal pumping assay, ten worms were placed 158 on NGM assay plates containing various concentrations of drugs, allowed to adapt for 30 min, 159 then, the number of contractions of the pharyngeal bulb was counted for 20 s for each worm. For 160 the aldicarb assay, the NGM plates were supplemented with 1 mM aldicarb. Thirty worms were 161 placed onto the assay plates, observed every 30 min and scored as moving or paralyzed worms.
162
Paralyzed worms did not move when poked by the worm pick. For the locomotion assay, ten 163 young adult worms were placed on NGM plates seeded with OP50 E. coli. After adaptation for 5 164 min, the number of wiggles of the body was counted for 30 s for each worm. For the egg 165 retention assay, well-fed young adult worms were picked onto NGM plates with food and 166 allowed to grow for 24 h. The assayed worms were picked onto a slide with an agarose pad with 167 20 mM sodium azide, and observed under a Zeiss Axio2 microscope using the 100x objective 168 lens. The number of eggs in the belly were counted. All assays were repeated three times and 169 two-tail t-tests were used to compare the mutant strain with the control strain. Genetic screen for suppressors of egl-30(n686) 172 Synchronized L4 worms were treated with 50 µM ethyl methanesulfonate and shaken for 4 hrs.
173
The treated worms (P0) were collected and washed twice with M9 buffer and transferred onto 174 two NGM plates to grow for 24 hrs. Ten adult worms were transferred onto each of ten fresh 175 plates and allowed to lay eggs for 4 hrs. Then they were transferred onto another ten fresh plates 176 and allowed to lay eggs (F1) overnight. After they grew to adulthood, ten F1 worms were 177 transferred onto 60 NGM plates containing 250 or 350 µM clozapine, and allowed to lay eggs 178 (F2) overnight. After 1-2 days, ten surviving F2 worms were transferred onto each of 60 NGM 179 plates and allowed to grow to adulthood. Then six F2 worms were transferred onto NGM plates Worms were grown on 10-20 8.5 cm NGM plates until they were gravid adults, then washed 188 with M9 buffer into a 50 ml tube and centrifuged at 2000xg for 3 min. The supernatant was 189 removed and 30 ml of bleach solution was added. Then the tube was inverted for 7-10 min until 190 all the worms were dissolved, followed by centrifugation at 1500xg for 1 min to collect eggs.
191
The eggs were washed once with M9 buffer, transferred onto 10 5.5 cm unseeded NGM plates, The sequencing results were analyzed at the high-performance computation facility of the 201 Partners Healthcare System. The reads were mapped to the reference genome (WS220) with 202 Bowtie-0.12.7, and the variant calls were done with Samtools. The variants were checked in igv. 203 We only focused on mutations that occurred in coding regions and splicing sites at which 204 variants could potentially cause disturbance of protein structures.
206
Strains are available upon request. 209 There are six dopamine receptor orthologs in the C. elegans genome, and mutants in each 210 ortholog are available. We performed developmental assays by growing the mutants and wild 211 type worms in plates treated with 0, 300, 400, and 500 µM clozapine. As shown in Fig. 1A , the 212 lethality rate of wild type worms was high and surviving worms were at the L1 stage. By were not resistant to clozapine, suggest that both dop-1 and dop-2 mediate effects of clozapine, 218 but dop-3 does not. We also tested mutants of the other three dopamine receptors, dop-4, dop-5 219 and dop-6, and found that dop-4 and dop-5 mutants were resistant to the effects of clozapine, but 220 dop-6 mutants were not ( Fig. 1B ).
207

Results
208
Dopamine receptors mediate effects of clozapine
222
Gαq proteins mediate effects of clozapine 223 Dopamine receptors are G protein coupled, and the alpha subunit of G protein has been found to 224 be associated with the effects of clozapine in mammalian models. To test for this association in 225 C. elegans, we studied mutants of the Gαq ortholog, egl-30, in worms. Compared to wild type, 226 the lethality rate of a reduction of function (rf) mutant, egl-30(n686), was dramatically increased 227 and development was delayed. Conversely, the lethality rate of a constitutively active mutant, 228 egl-30(js126), was slightly reduced and development was promoted ( Fig. 2A ). To confirm this 229 observation, we conducted drug assays on two other rf mutant alleles, egl-30(ad810) and egl-230 30(n715n1190), and found that they were also susceptible to clozapine (Fig. 2B ). We also tested 231 two worm strains carrying the integrated transgene of egl-30 DNA sequence in either wild type 232 background or an egl-30 mutation background, supposed to have higher Gαq level than wild 233 type, and found that they both reduced lethality rates and promoted development, compared to 234 wild type ( Fig. 2B ). The egl-30 gene is expressed ubiquitously and required for worm viability, locomotion, egg 239 laying, synaptic transmission and pharyngeal pumping. We used egg laying and locomotion 240 phenotypes to study downstream behavioral effects of changes in Gq signaling pathways. We 241 also studied one pathway related to synaptic transmission. Gα protein-involved signaling 242 controls the release of acetylcholine and other neuropeptides ( Fig. 3 ).
244
We performed developmental drug assays on three types of Gα proteins, goa-1 (Gαo), gpa-12 245 (Gα12), gsa-1 (Gαs) and found that their mutants are no different than wild type in response to 246 clozapine ( Fig. 3 and Table 1 ).
248
In the Gq and Gαs signaling pathways, we conducted developmental drug assays on the 249 downstream components of the Gq signaling pathway, namely, egl-8, unc-73, dgk-1, unc-13, 250 pkc-1, and found that dgk-1 suppressed the effects of clozapine, while egl-8 was similar to wild 251 type or slightly suppressed the effects of clozapine. By comparison, unc-73, unc-13, and pkc-1 252 strains all responded to clozapine the same as wild type strains (Table 1 ). In addition, 253 developmental drug assays performed on the downstream components of the Gαs signaling 254 pathway, acy-1, pde-4, and kin-2, showed that they all responded to clozapine the same as wild 255 type strains (Table 1 ). These observations suggested that these known downstream components 256 of Gq and other Gα signaling pathways were not involved in mediating the effects of clozapine.
258
Gαq modulators alter effects of clozapine 259 We investigated the role of modulators of Gαq by conducting developmental assays and 260 discovered that mutants of ric-8, a non-receptor activator of Gαq in both C. elegans and 261 mammals, are resistant to clozapine (Fig. 3 , Table 1 ). Mutants of three other modulators of Gαq, 262 cnb-1, eat-16, and rsbp-1 were found to be more susceptible to clozapine (Table 1) .
264
Isolation and characterization of Gαq mutant suppressors of clozapine effects 265 We performed a forward genetic screen for suppressors of egl-30(n686), taking advantage of the 266 hypersensitivity of egl-30(n686) to clozapine. We found eight mutants that were more resistant 267 to clozapine than egl-30(n686), and these suppressors were named EAB66-71 and EAB73-74.
268
The strongest suppressor was EAB66, which was even more resistant to clozapine than wild type 269 (data not shown). We characterized these mutants for other behavioral phenotypes and compared 270 them to wild type and egl-30(n686) worms. Aldicarb is an inhibitor of cholinesterase, causing 271 rapid accumulation of acetylcholine at the synaptic cleft, and thereby paralysis of the worms. The egl-30(n686) mutant is resistant to aldicarb compared to wild type. The suppressor EAB66 is 273 phenotypically like the wild type worm, whereas EAB67 remains phenotypically like the egl-274 30(n686) worm (Fig. 4A ). In the locomotion assay, strains carrying the suppressor EAB66 move 275 faster than egl-30(n686), but they do not move at the wild type level; whereas the EAB67 strain 276 is even slower than egl-30(n686) (Fig. 4B) . As for the egg retention assay, EAB66 and EAB67 277 strains are both more similar to egl-30(n686) strains than wild type worms (Fig. 4C ). However, 278 in the pharyngeal pumping assay, all the suppressors show activity that is statistically 279 significantly different from egl-30(n686), except EAB73 at 450 µM (Fig. 4D) .
281
Candidate genes for Gαq suppressors revealed by whole-genome sequencing 282 To identify the specific genes coding for the suppressor mutants, we performed whole-genome 283 sequencing of these mutants and compared the sequences of wild type and egl-30(n686) worms.
284
As shown in Table 2 , there are two to five mutations occurring in these mutants, each of which 285 changes protein coding sequences. Most of the mutations introduce a stop codon in a coding 286 region; but there are four mutations that change splicing sites; and one mutation changes the 287 initial start codon (M/V) in EAB68 (Table 2) . (Fig. 1) . These findings cannot be explained by the simple model in 293 which the two types of dopamine receptors have purely opposite and competing effects at the 294 level of production of cAMP, through activation of Gαs and Gαo. Our observation that neither 295 Gαs nor Gαo mutants display behavioral differences from wild type strains in drug assays is also 296 consistent with a more complex interaction of dopamine receptors and G proteins (Table 1) . 297 Notably, there is growing evidence that G protein coupled receptors (GPCRs) execute their Based on our genetic studies on the components in the four G protein-involved signaling 307 networks (Fig. 2, Table 1 ), only Gq and its modulators appear to strongly mediate the effects of 308 clozapine. The classical model that Gs and Go balance cAMP production and metabolism is not (Fig. 2) , the goa-1 (Gαo) mutant does not display a resistant phenotype upon clozapine 317 treatment (Table 1) . Furthermore, the downstream components, i.e., in the PLC signaling 318 pathway that facilitates synaptic transmission by body-wall muscle motor neurons, do not appear 319 to mediate clozapine effects, as their mutants have the same response as wild type strains (Table   320 1). Taken together, these observations indicate that the effects of clozapine on worm 321 development are not mediated by these known Gαq downstream signaling elements.
323
To explore how Gq proteins mediate the effects of clozapine, we performed a genetic screen and 324 identified eight suppressing mutants that were more resistant to the behavioral effects of 325 clozapine than the rf of egl-30 strain. Since the rf of egl-30 exhibited phenotypes including 326 decreased pharyngeal pumping and locomotion rates, reduced sensitivity to aldicarb, and high 327 retention of eggs, we tested whether these behaviors were affected by the suppressing mutations. 328 We tested two suppressors, EAB66 and EAB67, and found that aldicarb sensitivity, locomotion 329 rate and egg retention were changed at baseline in ways similar to egl-30, but EAB66 and 330 EAB67 did not have the characteristics of egl-30 in altering response to clozapine (Fig. 4) . The 331 genes affected by these suppressors might not be involved in the developmental/lethality 332 phenotypes induced by clozapine. In contrast, the pharyngeal pumping rates of all the 333 suppressors recovered to the wild type levels (Fig. 4) , indicating that this behavior does 334 correspond to the effects of clozapine on development, which is in agreement with our 335 previously reported findings (HAO et al. 2016 ).
337
Whole-genome sequencing revealed that each mutant strain carried 2-5 mutations that would 338 likely change protein structures. Most of the candidate genes in these suppressors are novel.
339
Further studies may identify the components that mediate the effects of clozapine through the Gq 340 protein.
342
In summary, we studied the actions of clozapine, using C. elegans as a genetic model, and 343 observed that both type I and type II dopamine receptors mediate the behavioral effects of 344 clozapine. Further, the results suggest that dopamine receptors form oligomers to signal through 345 Gq proteins. We also found that clozapine exerts its function on development by modulating Gq 346 signaling, which controls the pharyngeal pumping rate. The mutants we identified can be studied 347 further and those studies promise more interesting discoveries involving Gq signaling and a 348 better understanding of the mechanism of action and effects of clozapine beyond its direct effects 349 on cell surface receptors. There are statistically significant differences in phenotype among these four strains, P<0.001. 
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